Bell's Palsy

Overview

Bell's palsy is an acute, idiopathic, unilateral lower motor neuron (LMN) facial nerve (cranial nerve VII) palsy. It represents the most common cause of acute unilateral facial weakness, accounting for 60-75% of all cases of peripheral facial paralysis. [1,2] The condition is characterized by sudden-onset weakness affecting all muscles of facial expression on one side, including the forehead, which distinguishes it from upper motor neuron (UMN) lesions such as stroke.

The pathophysiology is believed to involve reactivation of herpes simplex virus type 1 (HSV-1) within the geniculate ganglion, leading to inflammation, edema, and compression of the facial nerve within the narrow confines of the facial canal. [3,4] While the exact etiology remains incompletely understood (hence "idiopathic"), viral reactivation with subsequent immune-mediated inflammation is the leading hypothesis.

Bell's palsy is a clinical diagnosis of exclusion. The critical initial task is differentiating peripheral facial weakness (Bell's palsy) from central facial weakness (stroke or other intracranial pathology). Early treatment with corticosteroids within 72 hours of symptom onset significantly improves the likelihood of complete recovery. [5,6] Eye protection is essential to prevent corneal complications from lagophthalmos (incomplete eyelid closure). Most patients (70-85%) achieve complete recovery, but prognostic factors including severity, age, and presence of complete paralysis influence outcomes. [7]

---

Critical Alerts

Must-Not-Miss Differentials

Rule out stroke: Central (UMN) facial weakness spares the forehead due to bilateral cortical innervation of the upper facial muscles; peripheral (LMN) Bell's palsy involves the entire hemiface including forehead. [8]

Ramsay Hunt syndrome (herpes zoster oticus): Presence of vesicles in the external auditory canal, ear pain, or ipsilateral hearing loss suggests varicella-zoster virus (VZV) reactivation—requires antiviral therapy in addition to corticosteroids and has worse prognosis. [9]

Lyme disease: In endemic areas, facial palsy (especially if bilateral) may represent neuroborreliosis—requires antibiotic treatment, not steroids. [10]

Bilateral facial weakness: Never typical Bell's palsy—consider Guillain-Barré syndrome, sarcoidosis, Lyme disease, or carcinomatous meningitis. [11]

Essential Immediate Actions

1. Eye protection: Prevent exposure keratopathy with artificial tears, lubricating ointment, and nighttime taping/patching
2. Corticosteroids within 72 hours: Prednisolone 60-80 mg daily for 7-10 days improves complete recovery rates from 70% to 85%
3. Reassurance: Educate patients that 70-85% achieve full recovery within 3-6 months

---

Central vs Peripheral Facial Weakness: The Critical Distinction

Clinical Pearl: If the patient cannot wrinkle their forehead or raise their eyebrow on the affected side, the lesion is peripheral (LMN). If forehead strength is preserved, suspect a central lesion (stroke) and initiate stroke protocol immediately. [8]

---

Epidemiology

Incidence and Prevalence

Bell's palsy has an annual incidence of 15-30 cases per 100,000 population, with approximately 40,000 new cases annually in the United States. [1,2] The condition shows no significant gender predilection, affecting men and women equally. While Bell's palsy can occur at any age, the incidence is highest in individuals aged 15-45 years, with a second smaller peak in those over 60 years. [7]

Risk Factors

Geographic and Seasonal Variation

Some studies suggest higher incidence in winter months, possibly related to increased respiratory viral infections. [14] No consistent racial or ethnic predilection has been identified, though some series report slightly higher rates in individuals of Asian descent.

---

Aetiology and Pathophysiology

Proposed Viral Etiology

The "idiopathic" nature of Bell's palsy has been increasingly challenged by molecular evidence implicating herpes simplex virus type 1 (HSV-1) as the primary trigger. Murakami et al. (1996) identified HSV-1 DNA in endoneurial fluid and posterior auricular muscle from patients with Bell's palsy, providing strong evidence for viral reactivation within the geniculate ganglion. [3] Other implicated viruses include:

• HSV-1: Most strongly associated (detected in 60-80% of cases via PCR)
• Varicella-zoster virus (VZV): Causes Ramsay Hunt syndrome (herpes zoster oticus)
• Epstein-Barr virus (EBV): Rare association
• Cytomegalovirus (CMV): Primarily in immunocompromised patients

Pathophysiological Cascade

Exam Detail: The current understanding of Bell's palsy pathogenesis involves a multi-step process:

1. Viral Reactivation: Latent HSV-1 in the geniculate ganglion reactivates, possibly triggered by stress, immunosuppression, or upper respiratory infection.

2. Inflammatory Response: Viral replication induces local inflammation with release of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), attracting lymphocytes and macrophages.

3. Edema and Compression: The facial nerve travels through the facial canal (fallopian canal), a rigid bony tunnel. Inflammation causes nerve edema, but the inflexible canal prevents expansion, resulting in compression.

4. Ischemia: Compression of the vasa nervorum (blood vessels supplying the facial nerve) leads to nerve ischemia, particularly in the narrowest segment of the canal at the meatal foramen and labyrinthine segment.

5. Demyelination: Early ischemia causes segmental demyelination (neuropraxia), which is reversible. This explains rapid recovery in mild cases.

6. Axonal Degeneration: If compression is severe or prolonged, Wallerian degeneration (axonotmesis or neurotmesis) occurs distal to the site of injury. This requires axonal regeneration, which takes months and may be incomplete, leading to residual weakness or synkinesis.

7. Recovery: Spontaneous decompression occurs as inflammation resolves. Remyelination and/or axonal regeneration restore function. Corticosteroids hasten resolution of inflammation and edema, reducing the risk of irreversible axonal injury.

Anatomy of the Facial Nerve (CN VII)

Understanding facial nerve anatomy is essential for clinical localization:

Intracranial Course:

• Motor nucleus in pons
• Nerve exits brainstem at cerebellopontine angle with CN VIII
• Enters internal auditory meatus

Intratemporal Course (within temporal bone):

1. Labyrinthine segment: Narrowest portion, most vulnerable to compression
2. Geniculate ganglion: Contains sensory cell bodies; site of HSV latency
3. Tympanic (horizontal) segment: Crosses medial wall of middle ear
4. Mastoid (vertical) segment: Descends to stylomastoid foramen

Branches (proximal to distal):

• Greater petrosal nerve (geniculate ganglion): Parasympathetic to lacrimal gland
• Nerve to stapedius (tympanic segment): Motor to stapedius muscle
• Chorda tympani (mastoid segment): Taste to anterior 2/3 tongue, parasympathetic to submandibular/sublingual glands
• Posterior auricular nerve (extratemporal): Motor to occipitalis and auricular muscles
• Five terminal branches (extratemporal): Temporal, zygomatic, buccal, marginal mandibular, cervical—motor to facial expression muscles

Clinical Localization:

• Loss of taste (ageusia) or reduced salivation suggests lesion proximal to chorda tympani branch
• Hyperacusis suggests lesion proximal to nerve to stapedius
• Reduced lacrimation suggests lesion at or proximal to greater petrosal nerve (geniculate ganglion)
• Isolated facial weakness with no autonomic/sensory features suggests lesion distal to all branches (stylomastoid foramen or extratemporal)

Bell's palsy typically affects the facial nerve in the labyrinthine or geniculate ganglion region, explaining the common co-occurrence of hyperacusis, taste disturbance, and reduced lacrimation.

---

Clinical Presentation

Symptom Timeline

Prodrome (0-3 days before weakness):

• Retroauricular or postauricular pain (50-60% of patients)
• Ipsilateral ear discomfort or otalgia
• Subjective facial numbness or tingling
• Recent viral upper respiratory infection symptoms (50%)

Acute Phase (onset over hours to 72 hours):

• Unilateral facial weakness reaching maximum severity within 72 hours (usually 24-48 hours)
• Inability to close eye on affected side
• Mouth droop, drooling, difficulty with eating and speaking
• Loss of nasolabial fold
• Inability to raise eyebrow or wrinkle forehead

Associated Symptoms:

• Hyperacusis (30%): Increased sensitivity to sounds due to stapedius muscle paralysis
• Dysgeusia (50-60%): Altered or lost taste sensation on anterior 2/3 of tongue (chorda tympani involvement)
• Dry eye or epiphora (paradoxical tearing): Reduced lacrimation leads to dry eye, but reflex tearing from corneal irritation causes watering
• Difficulty with articulation: Labial sounds (b, p, m) affected
• Drooling and difficulty retaining food/fluid in mouth

Cardinal Signs on Examination

Facial Muscle Weakness (assess each region):

Special Signs:

• Bell's phenomenon: Normal protective reflex where the eyeball rotates upward and outward when attempting to close the eye. This protective mechanism helps prevent corneal damage even when eyelid closure is incomplete.
• Schirmer test: Can assess lacrimation (rarely performed in acute setting)

Ear Examination:

• Essential: Inspect external auditory canal for vesicles
• Presence of vesicles = Ramsay Hunt syndrome (VZV), not Bell's palsy
• Check for signs of otitis media or mastoiditis

Cranial Nerve Examination:

• CN VIII (vestibulocochlear): Assess hearing—if reduced, consider cerebellopontine angle pathology
• Other CNs: Should be normal; if multiple CN deficits present, consider brainstem or skull base lesion

Neurological Examination:

• Motor and sensory: Limbs should be normal
• Gait and coordination: Normal
• If any non-CN VII deficits present: Suspect alternative diagnosis (stroke, GBS, brainstem lesion)

Grading Severity: House-Brackmann Scale

The House-Brackmann Facial Nerve Grading System is the most widely used classification for severity and prognosis. [15]

Prognostic Significance: House-Brackmann grade IV-VI at presentation indicates higher risk of incomplete recovery and need for consideration of antiviral therapy (though controversial). Grade I-III typically have excellent prognosis with corticosteroid treatment.

Alternative Grading Systems: Sunnybrook and eFACE scales provide more granular assessment and are increasingly used in research settings. [16]

---

Red Flags and Atypical Features

Features Suggesting Alternative Diagnosis

---

Differential Diagnosis

Bell's palsy is a diagnosis of exclusion after ruling out other causes of acute peripheral facial weakness.

Common Differentials

1. Stroke (Central Facial Weakness)

• Key distinguishing feature: Forehead spared (can wrinkle forehead and raise eyebrow)
• Associated with limb weakness, dysarthria, dysphagia, sensory deficits, visual field cuts
• Sudden onset (seconds to minutes)
• Older age, vascular risk factors
• Management: Activate stroke protocol, CT head non-contrast, consider thrombolysis

2. Ramsay Hunt Syndrome (Herpes Zoster Oticus)

• VZV reactivation in geniculate ganglion
• Triad: (1) Facial palsy, (2) Otalgia, (3) Vesicles in external auditory canal or on auricle
• May have ipsilateral hearing loss, vertigo, tinnitus
• Worse prognosis than Bell's palsy (50-60% complete recovery vs 70-85%)
• Management: Antiviral (valacyclovir 1g TID × 7 days) + corticosteroids [9]

3. Lyme Disease (Neuroborreliosis)

• Tick exposure, erythema migrans rash (may have resolved)
• Can cause bilateral facial palsy (25% of Lyme facial palsies are bilateral)
• Endemic areas: Northeastern US, upper Midwest, Northern California, Europe
• May have meningeal signs, radiculopathy
• Management: Doxycycline 100mg BD or amoxicillin 500mg TID × 14-21 days; avoid steroids [10]

4. Otitis Media / Mastoiditis / Cholesteatoma

• Ear pain, otorrhea, fever
• Tenderness over mastoid
• Tympanic membrane abnormalities on otoscopy
• Management: CT temporal bones, ENT referral, antibiotics ± surgical drainage

5. Guillain-Barré Syndrome (GBS)

• Bilateral facial weakness in 50% of GBS cases
• Ascending weakness, areflexia, sensory symptoms
• CSF: albuminocytologic dissociation (elevated protein, normal cell count)
• Management: IVIG or plasmapheresis, ICU monitoring for respiratory failure

6. Parotid Tumors

• Gradual onset over weeks to months
• Palpable parotid mass
• Malignant parotid tumors (mucoepidermoid, adenoid cystic carcinoma) can invade facial nerve
• Management: MRI, ENT referral, biopsy/excision

7. Cerebellopontine Angle (CPA) Tumors

• Vestibular schwannoma (acoustic neuroma) most common
• Ipsilateral hearing loss, tinnitus, vertigo
• Gradual onset
• Management: MRI brain with gadolinium

8. Sarcoidosis

• Bilateral facial palsy, uveitis, parotid swelling (Heerfordt syndrome)
• Systemic features: erythema nodosum, lymphadenopathy, pulmonary involvement
• Management: Serum ACE, chest X-ray, biopsy, steroids

9. Trauma

• Temporal bone fracture (usually longitudinal)
• Clear history of head trauma
• May have hemotympanum, CSF otorrhea, hearing loss
• Management: CT temporal bones, neurosurgical consult

10. Other Infectious Causes

• HIV: Acute seroconversion or advanced disease
• Mycobacterium tuberculosis: TB meningitis
• Leptospirosis: Rare
• Malignant otitis externa: Pseudomonas infection in diabetics, skull base osteomyelitis

---

Investigations

Diagnosis is Clinical

Bell's palsy is a clinical diagnosis. In typical presentations (acute onset unilateral LMN facial palsy with forehead involvement, no atypical features, no other neurological deficits), no investigations are required. [6,17]

When to Investigate

Indications for MRI Brain with Gadolinium:

• Atypical features (gradual onset, recurrent same side, bilateral, other CN deficits)
• No improvement after 3-4 months
• House-Brackmann grade V-VI with no recovery
• Recurrent episodes
• Suspected tumor or structural lesion

MRI Findings in Bell's Palsy (if performed):

• Enhancement of facial nerve in the labyrinthine segment, geniculate ganglion, or distal mastoid segment on T1 post-gadolinium
• These findings are non-specific and not required for diagnosis

Indications for Laboratory Testing:

Indications for CT Temporal Bones:

• Suspected mastoiditis (otalgia, fever, mastoid tenderness)
• Suspected cholesteatoma (chronic otorrhea, conductive hearing loss)
• Suspected temporal bone fracture (trauma history)

Electrodiagnostic Studies:

• Electromyography (EMG) and electroneurography (ENoG) can assess degree of nerve degeneration
• Typically performed by neurologists or ENT specialists at 2-3 weeks after onset
• ENoG showing > 90% degeneration predicts poor prognosis and may guide surgical decompression decisions (controversial)
• Not routinely performed in primary care or emergency department settings

---

Management

Principles of Treatment

1. Corticosteroids within 72 hours: Only intervention with strong evidence for improving complete recovery
2. Eye protection: Essential to prevent sight-threatening corneal complications
3. Antiviral therapy: Controversial; may add marginal benefit in severe cases when combined with steroids
4. Reassurance: Most patients achieve complete recovery
5. Exclusion of serious differentials: Ensure not stroke, Ramsay Hunt, Lyme, GBS, or tumor

---

Corticosteroid Therapy

Evidence Base:

The landmark Sullivan et al. (2007) trial published in the New England Journal of Medicine randomized 551 patients with Bell's palsy to prednisolone, acyclovir, combination, or placebo within 72 hours of onset. Prednisolone significantly increased complete recovery at 3 and 9 months (83% vs 64%, NNT = 5), while acyclovir showed no benefit. [5]

A Cochrane systematic review (2015) confirmed that corticosteroids significantly increase the probability of complete recovery (RR 1.20, 95% CI 1.08-1.33; NNT = 10). [18]

American Academy of Neurology Practice Parameter (2012) gives Level A recommendation (established as effective) for corticosteroids in Bell's palsy. [6]

Regimen:

Timing: Most effective when started within 72 hours of symptom onset. Benefit decreases significantly after 72 hours. Some guidelines suggest steroids may still be beneficial if started within 7 days in severe cases. [17]

Contraindications and Cautions:

• Active tuberculosis (relative)
• Active peptic ulcer disease (relative)
• Uncontrolled diabetes (relative—monitor glucose closely; benefits usually outweigh risks)
• Pregnancy (prednisolone preferred; generally considered safe)
• Immunosuppression (benefits usually outweigh risks in Bell's palsy)

Side Effects: Short course is generally well-tolerated. Warn patients about hyperglycemia, insomnia, mood changes, dyspepsia.

---

Antiviral Therapy

Evidence Base:

The role of antiviral therapy in Bell's palsy remains controversial despite extensive research.

Sullivan et al. (2007): Acyclovir alone showed no benefit; acyclovir + prednisolone showed no additional benefit over prednisolone alone. [5]

Cochrane Review (2015): Gagyor et al. found no significant benefit of antivirals (acyclovir, valacyclovir) alone or in combination with corticosteroids for Bell's palsy. [18]

Meta-analyses: Some suggest modest benefit when antivirals are added to corticosteroids in severe cases (House-Brackmann IV-VI), but data are conflicting. [19,20]

Current Consensus:

• Not routinely recommended for typical Bell's palsy
• Consider in severe cases (House-Brackmann IV-VI) as an adjunct to corticosteroids, given low risk and theoretical benefit
• Essential in Ramsay Hunt syndrome (VZV reactivation)

If Used:

Combination Therapy: If using antivirals, always combine with corticosteroids; antivirals alone are not effective.

---

Eye Care (Essential)

Incomplete eyelid closure (lagophthalmos) leads to corneal exposure, desiccation, and risk of exposure keratopathy, which can cause corneal ulceration, scarring, and permanent visual impairment. Eye care is mandatory in all Bell's palsy patients with lagophthalmos.

Day-Time Protection:

• Artificial tears (preservative-free): Instill every 1-2 hours while awake
• Lubricating eye drops: Hypromellose, carbomer gel
• Protective eyewear: Glasses or moisture chamber goggles to reduce evaporation
• Avoid dust, wind, air conditioning: Exacerbates drying

Night-Time Protection (CRITICAL):

• Lubricating ointment: Lacri-Lube, Visco-Tears, or similar thick ointment applied at bedtime
• Eyelid taping: Hypoallergenic tape to gently close eyelid (tape from mid-eyelid to cheek in downward direction)
• Eye patch: Alternative to taping, but taping is generally more effective
• Moisture chamber: Specialized goggles for severe cases

Monitoring:

• Educate patient to monitor for eye pain, redness, vision changes
• Urgent ophthalmology referral if:
  • Severe lagophthalmos with incomplete closure despite maximal effort
  • Eye pain or redness develops
  • Vision changes
  • Corneal abrasion or ulcer suspected
  • Reduced corneal sensation (blink reflex impaired)

Surgical Options (for prolonged lagophthalmos):

• Gold weight implant in upper eyelid (temporary or permanent)
• Lateral tarsorrhaphy: Partial surgical closure of eyelid
• Botulinum toxin to levator palpebrae superioris (induces ptosis)

---

Physical Therapy and Facial Exercises

Evidence: Moderate-quality evidence suggests facial exercises (mime therapy, facial neuromuscular retraining) may improve facial function and reduce synkinesis in patients with prolonged weakness or incomplete recovery. [21] Exercises are unlikely to help in the acute phase but may be beneficial after 3-4 weeks if weakness persists.

Types of Exercises:

• Facial muscle stretching and massage
• Mirror feedback exercises
• Neuromuscular retraining
• Biofeedback techniques

Referral: Consider physiotherapy or specialist facial rehabilitation if no improvement by 4-6 weeks or if synkinesis develops.

---

Special Populations

Pregnancy:

• Bell's palsy incidence is 3-4 times higher in pregnancy, especially 3rd trimester and early postpartum. [13]
• Corticosteroids are generally safe in pregnancy (prednisolone preferred as it is minimally transferred across placenta)
• Eye care is essential
• Consider obstetric consultation if severe or near delivery
• Pre-eclampsia screening (10-fold increased risk of Bell's palsy in pre-eclampsia)

Diabetes:

• Higher incidence and potentially worse prognosis
• Corticosteroids may worsen glycemic control—monitor glucose closely, adjust diabetic medications as needed
• Benefits of steroids generally outweigh risks
• Diabetics are at higher risk of malignant otitis externa (Pseudomonas skull base osteomyelitis)—maintain high index of suspicion if otalgia persists

Children:

• Bell's palsy is less common in children but presentation and treatment are similar
• Always consider Lyme disease in endemic areas (Lyme disease is the leading cause of childhood facial palsy in endemic regions)
• Corticosteroid dosing: Prednisolone 1-2 mg/kg/day (max 60-80 mg) for 7-10 days
• Prognosis is excellent in children (> 90% complete recovery)

Immunocompromised Patients:

• Consider opportunistic infections (VZV, CMV, HIV, TB)
• Antivirals may be more strongly indicated
• Corticosteroids still beneficial but monitor for infection

---

Treatment of Specific Differential Diagnoses

Ramsay Hunt Syndrome (Herpes Zoster Oticus):

• Antiviral therapy is essential: Valacyclovir 1000 mg TID × 7-10 days OR acyclovir 800 mg 5 times daily × 7-10 days
• Corticosteroids: Prednisolone 60-80 mg daily × 7-10 days
• Analgesia: Often severe otalgia; may require opiates
• Eye care: As per Bell's palsy
• Prognosis: Worse than Bell's palsy (50-60% complete recovery vs 70-85%)

Lyme Disease Facial Palsy:

• Antibiotics (not steroids): Doxycycline 100 mg BD × 14-21 days OR amoxicillin 500 mg TID × 14-21 days OR ceftriaxone 2g IV daily × 14-28 days (if CNS involvement)
• Do not give corticosteroids in Lyme disease (may impair immune clearance of spirochetes)
• Lyme serology (ELISA + Western blot if positive)
• Lumbar puncture if meningeal signs or severe CNS symptoms

---

Complications

Acute Complications

Exposure Keratopathy (Most Important):

• Incidence: 15-20% if eye care not provided
• Corneal abrasion, ulceration, perforation, scarring, vision loss
• Prevention: Meticulous eye care as above
• Treatment: Ophthalmology referral, intensive lubrication, antibiotics if infected, surgical options

Psychological Impact:

• Facial disfigurement can cause significant distress, anxiety, depression
• Reassurance and education about high recovery rate are important
• Referral for psychological support if needed

Long-Term Complications (Incomplete Recovery)

Synkinesis (Aberrant Nerve Regeneration):

• Incidence: 15-20% of patients, especially those with severe initial paralysis or delayed recovery
• Mechanism: During regeneration, axons may re-innervate incorrect muscle targets, causing involuntary movements
• Examples:
  • Eye closure triggers mouth movement (ocular-oral synkinesis)
  • Smiling triggers eye closure
  • Eating triggers lacrimation ("crocodile tears")
• Management: Botulinum toxin injections, facial retraining exercises, surgical re-innervation (selective neurectomy)

Contracture:

• Chronic hypertonia and tightness of facial muscles on affected side
• Face appears "pulled" toward affected side at rest
• Management: Botulinum toxin, physiotherapy

Hemifacial Spasm:

• Involuntary twitching or spasm of facial muscles
• May be due to aberrant regeneration or vascular compression (microvascular decompression may be considered)

Residual Weakness:

• Persistent mild to moderate weakness affecting facial symmetry, speech, eating
• 15-30% of patients have some degree of residual weakness
• More common with severe initial paralysis, older age, diabetes, delayed treatment

Chronic Ocular Complications:

• Chronic dry eye, ectropion (outward turning of lower eyelid), epiphora

---

Prognosis

Natural History and Recovery

Untreated Bell's Palsy:

• Complete recovery: 60-70% within 6 months [7]
• Partial recovery: Additional 15-20%
• Persistent moderate-severe weakness: 10-15%

With Corticosteroid Treatment:

• Complete recovery: 80-85% within 3-6 months [5,6]
• Partial recovery: Additional 10%
• Persistent moderate-severe weakness: 5-10%

Timeline of Recovery:

• First signs of improvement: Usually within 2-3 weeks
• Significant improvement: By 3 months in most cases
• Maximal recovery: By 6-12 months

No improvement by 3-4 months: Consider MRI to exclude structural lesion or tumor; refer to neurology/ENT.

Prognostic Factors

Good Prognosis:

• Incomplete paralysis (House-Brackmann II-III)
• Early recovery (improvement within 2-3 weeks)
• Younger age (less than 40 years)
• Treatment with corticosteroids within 72 hours
• Absence of hyperacusis or complete ageusia (suggests less proximal nerve involvement)

Poor Prognosis:

• Complete paralysis (House-Brackmann V-VI)
• No recovery by 3-4 months
• Older age (> 60 years)
• Diabetes mellitus
• Ramsay Hunt syndrome (VZV)
• Severe retroauricular pain
• Electroneurography showing > 90% degeneration at 2 weeks

Recurrence

• Recurrence rate: 7-10% over lifetime [22]
• Recurrence usually affects the opposite side (70%), but can affect the same side (30%)
• Ipsilateral recurrence should raise suspicion for tumor, cholesteatoma, or structural lesion—requires MRI
• Familial recurrence (multiple family members affected) suggests genetic predisposition

---

Prevention and Screening

Primary Prevention:

• No established primary prevention strategies exist for Bell's palsy
• Optimization of diabetes control may reduce incidence in diabetic patients
• Avoidance of triggers (stress, sleep deprivation) may reduce recurrence risk (theoretical, not evidence-based)

Screening:

• No screening programs exist
• Patients with recurrent Bell's palsy may warrant MRI to exclude structural lesions

---

Key Guidelines and Recommendations

American Academy of Neurology (AAN) Practice Parameter (2012) [6]

Level A Recommendations (Established as Effective):

• Oral steroids should be offered to increase the probability of good facial functional recovery (strong evidence)

Level B Recommendations (Probably Effective):

• Oral steroids should be offered within 72 hours of symptom onset to increase the probability of complete facial functional recovery (moderate evidence)
• Antivirals (acyclovir, valacyclovir) have not been shown to improve facial functional recovery when used alone and should not be offered as monotherapy (moderate evidence)

Level C Recommendations (Possibly Effective):

• Combination therapy (antivirals + steroids) may be offered to increase the probability of complete recovery in patients with severe facial palsy (House-Brackmann V-VI), though evidence is weak

Level U (Insufficient Evidence):

• Surgical decompression has insufficient evidence to support or refute its use

American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) Clinical Practice Guideline (2013) [17]

Strong Recommendations:

1. Clinicians should offer corticosteroids to patients with Bell's palsy within 72 hours of symptom onset
2. Clinicians should educate patients with incomplete eye closure about eye protection strategies

Recommendations:

1. Clinicians should not routinely obtain laboratory testing or imaging in patients with a compatible clinical history and examination
2. Clinicians may offer antiviral therapy in combination with corticosteroids for Bell's palsy

Key Action Statements:

• Eye care and education are mandatory for all patients with lagophthalmos
• Electrodiagnostic testing is not routinely recommended but may guide prognosis in severe cases
• Surgical decompression is not routinely recommended

---

Exam-Focused Points

Common MRCP / PACES Exam Questions

1. "How would you differentiate Bell's palsy from a stroke?"

Model Answer: "The key distinction is between upper motor neuron (UMN) and lower motor neuron (LMN) facial weakness. In Bell's palsy, the lesion is in the facial nerve itself (LMN), affecting all muscles of facial expression on one side, including the forehead. The patient cannot raise their eyebrow or wrinkle their forehead on the affected side. In contrast, a stroke or other central lesion (UMN) spares the forehead due to bilateral cortical innervation of the upper facial muscles—the patient can still raise their eyebrow. Additionally, stroke typically presents with sudden onset (seconds), associated limb weakness, dysarthria, or sensory deficits, whereas Bell's palsy is an isolated facial weakness evolving over hours to 2-3 days with no other neurological signs."

---

2. "What is your management approach to a patient presenting with acute unilateral facial weakness?"

Model Answer: "I would approach this systematically:

Initial Assessment:

• Take a focused history: onset (sudden vs rapid), associated symptoms (ear pain, vesicles, rash, tick bite), other neurological symptoms (limb weakness, speech, vision)
• Examination: Assess forehead involvement (raise eyebrows), eye closure, smile, puff cheeks, and assess for other cranial nerve or limb deficits

Differentiate UMN vs LMN:

• If forehead is spared → suspect central cause (stroke) → activate stroke protocol
• If forehead is involved → peripheral facial palsy

Rule Out Secondary Causes:

• Examine ears for vesicles (Ramsay Hunt), otitis media, mastoiditis
• Assess for bilateral weakness (GBS, Lyme, sarcoidosis)
• Ask about Lyme risk (endemic area, tick exposure)

Diagnosis: If unilateral LMN facial palsy with forehead involvement, no vesicles, no other CN deficits, no Lyme risk → clinical diagnosis of Bell's palsy

Management:

1. Corticosteroids: Prednisolone 60-80 mg daily for 7-10 days if within 72 hours of onset
2. Eye protection: Artificial tears hourly, lubricating ointment and tape at night, education about corneal protection
3. Antivirals: Consider if severe (House-Brackmann IV-VI) as adjunct to steroids
4. Reassurance: 80-85% complete recovery with treatment
5. Exclude differentials: No imaging needed if typical presentation

Follow-Up: Review in 2-4 weeks; if no improvement by 3-4 months, refer for MRI and specialist review."

---

3. "A 32-year-old woman in the 3rd trimester of pregnancy presents with acute unilateral facial weakness. How would you manage her?"

Model Answer: "Pregnancy is a risk factor for Bell's palsy, with a 3-4 fold increased incidence, particularly in the 3rd trimester and early postpartum. I would:

1. Confirm diagnosis: LMN facial palsy with forehead involvement, no stroke features, no other causes
2. Assess for pre-eclampsia: Check blood pressure, urine protein, as pre-eclampsia is associated with 10-fold increased risk of Bell's palsy
3. Treatment:
   • Prednisolone 60-80 mg daily × 7-10 days: Safe in pregnancy (prednisolone is preferred over dexamethasone/betamethasone as it is minimally transferred across placenta); benefits outweigh minimal fetal risk
   • Eye protection: As per standard care
   • Antivirals: Acyclovir category B in pregnancy; consider if severe, though evidence is weak
4. Obstetric consultation: Inform obstetric team given association with pre-eclampsia
5. Reassurance: Prognosis is similar to non-pregnant patients; most recover fully

Note: Corticosteroids are not contraindicated in pregnancy for Bell's palsy, and withholding treatment risks permanent facial weakness, which is a greater harm than the minimal fetal risk."

---

4. "What are the causes of bilateral facial weakness?"

Model Answer: "Bilateral facial weakness is never typical Bell's palsy and requires investigation for systemic or multifocal disease. Causes include:

Neurological:

1. Guillain-Barré Syndrome (most common): Ascending areflexic paralysis, 50% have facial involvement, CSF shows albuminocytologic dissociation
2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Chronic progressive GBS variant
3. Motor neuron disease: Rare, progressive bulbar weakness
4. Myasthenia gravis: Fatigable weakness, positive edrophonium test, acetylcholine receptor antibodies

Infectious: 5. Lyme disease (neuroborreliosis): 25% of Lyme facial palsies are bilateral, tick exposure, endemic area 6. HIV seroconversion: Acute retroviral syndrome 7. Tuberculous meningitis: Subacute, meningism, basal meningitis affects CN VII bilaterally

Infiltrative: 8. Sarcoidosis: Heerfordt syndrome (uveitis, parotid swelling, facial palsy, fever), bilateral hilar lymphadenopathy 9. Carcinomatous meningitis: Malignant infiltration of meninges (breast, lung, melanoma)

Structural: 10. Bilateral acoustic neuromas: Neurofibromatosis type 2

Metabolic/Hereditary: 11. Melkersson-Rosenthal syndrome: Triad of recurrent facial palsy, fissured tongue, facial edema 12. Moebius syndrome: Congenital absence of CN VI and VII nuclei

Investigation: Bilateral facial weakness requires urgent investigation including MRI brain, LP (cells, protein, cytology), Lyme serology, ACE level, chest X-ray, and often admission for monitoring."

---

5. "What is Ramsay Hunt syndrome and how does it differ from Bell's palsy?"

Model Answer: "Ramsay Hunt syndrome, also known as herpes zoster oticus, is peripheral facial palsy caused by reactivation of varicella-zoster virus (VZV) in the geniculate ganglion.

Classic Triad:

1. Acute peripheral facial palsy
2. Otalgia (ear pain)
3. Vesicles in the external auditory canal, on the auricle, or over the tympanic membrane

Additional Features:

• Ipsilateral hearing loss, tinnitus, vertigo (CN VIII involvement)
• Vesicles may extend to anterior 2/3 of tongue, soft palate (sensory distribution of CN VII)
• More severe pain than Bell's palsy

Differences from Bell's Palsy:

• Etiology: VZV (not HSV-1)
• Clinical features: Vesicles, severe otalgia, hearing loss
• Treatment: Antivirals are essential (valacyclovir 1g TID × 7-10 days) + corticosteroids (prednisolone 60-80 mg × 7-10 days)
• Prognosis: Worse than Bell's palsy—only 50-60% achieve complete recovery vs 80-85% in Bell's palsy [9]

Key Point: The presence of vesicles in the ear canal transforms a presumed Bell's palsy into Ramsay Hunt syndrome, mandating antiviral therapy in addition to corticosteroids."

---

Viva Preparation

Viva Point: Opening Statement for Viva: "Bell's palsy is an acute, idiopathic, unilateral lower motor neuron facial nerve palsy, representing the most common cause of peripheral facial weakness with an annual incidence of 15-30 per 100,000. The condition is believed to be caused by HSV-1 reactivation leading to inflammation and compression of the facial nerve within the facial canal. The hallmark clinical feature is sudden-onset weakness of all ipsilateral facial muscles, including the forehead, which distinguishes it from central (UMN) causes such as stroke. Early treatment with corticosteroids within 72 hours significantly improves the likelihood of complete recovery from 70% to 85%."

Key Statistics to Quote:

• Incidence: 15-30 per 100,000 per year [1,2]
• Complete recovery with steroids: 80-85% [5,6]
• Complete recovery without treatment: 60-70% [7]
• Recurrence rate: 7-10% [22]
• Ramsay Hunt recovery: 50-60% [9]
• NNT for corticosteroids: 5-10 [5,18]

Classifications to Know:

• House-Brackmann Facial Nerve Grading Scale (I-VI): Grade I normal, Grade VI complete paralysis [15]
• Differentiate UMN (forehead spared) vs LMN (forehead involved) [8]

Evidence to Cite:

• Sullivan et al., NEJM 2007: Prednisolone increased complete recovery to 83% vs 64% placebo; acyclovir showed no benefit [5]
• Cochrane Review 2015: Corticosteroids RR 1.20 for complete recovery, NNT = 10 [18]
• AAN Practice Parameter 2012: Level A recommendation for corticosteroids [6]
• Murakami et al., 1996: HSV-1 DNA identified in endoneurial fluid in Bell's palsy [3]

Red Flags to Mention:

• Forehead sparing → stroke, not Bell's palsy
• Bilateral facial weakness → GBS, Lyme, sarcoidosis
• Vesicles in ear → Ramsay Hunt (needs antivirals)
• Gradual onset → tumor (needs MRI)

Complications and Sequelae:

• Acute: Exposure keratopathy (15-20% without eye care)
• Chronic: Synkinesis (15-20%), residual weakness (15-30%), hemifacial spasm

Management Controversies:

• Antivirals: Sullivan 2007 showed no benefit; Cochrane 2015 confirmed no benefit; some meta-analyses suggest possible marginal benefit in severe cases when combined with steroids—current consensus is not to use routinely
• Surgical decompression: Controversial, no high-quality RCT evidence; not routinely recommended

---

Common Mistakes That Fail Candidates

❌ Failing to distinguish UMN from LMN facial weakness: Not examining forehead function is a critical error. Always assess if patient can raise eyebrow and wrinkle forehead.

❌ Missing Ramsay Hunt syndrome: Not examining the external auditory canal for vesicles; if vesicles present, antivirals are essential.

❌ Not prescribing eye protection: Exposure keratopathy is preventable and can cause permanent vision loss—eye care is mandatory.

❌ Prescribing antivirals alone: Antivirals without steroids are ineffective. If using antivirals, always combine with corticosteroids.

❌ Not recognizing bilateral facial weakness as atypical: Bilateral facial palsy is never Bell's palsy—think GBS, Lyme, sarcoidosis.

❌ Giving steroids for Lyme disease: Lyme facial palsy requires antibiotics (doxycycline or amoxicillin), not steroids.

❌ Ordering unnecessary imaging in typical Bell's palsy: Uncomplicated Bell's palsy is a clinical diagnosis; MRI is not required unless atypical features present.

❌ Failing to provide reassurance: Not explaining the excellent prognosis (80-85% complete recovery with steroids) causes unnecessary anxiety.

❌ Not arranging follow-up: Patients must be reviewed at 2-4 weeks; if no improvement by 3-4 months, MRI and specialist referral are needed.

---

Clinical Pearls

Diagnostic Pearls

💎 Forehead test is definitive: If the patient can raise their eyebrow on the affected side, it's not Bell's palsy—consider stroke or other UMN lesion.

💎 Bell's phenomenon is protective: The normal upward rotation of the eye with attempted closure (Bell's phenomenon) helps protect the cornea even when eyelid closure is incomplete, but is not a substitute for active eye protection measures.

💎 Bilateral facial weakness is NEVER Bell's palsy: Always investigate for GBS, Lyme, sarcoidosis, or carcinomatous meningitis.

💎 Gradual onset over weeks = tumor until proven otherwise: Bell's palsy reaches maximal weakness within 72 hours (usually 24-48 hours); if progression continues beyond 1 week, suspect neoplasm and order MRI.

💎 Recurrence on the same side is atypical: Most recurrences (70%) affect the opposite side; ipsilateral recurrence raises suspicion for tumor or cholesteatoma.

💎 Hyperacusis indicates proximal facial nerve involvement: Stapedius branch arises in the tympanic segment; hyperacusis suggests lesion at or proximal to this level.

Treatment Pearls

💎 72-hour window for steroids is critical: Efficacy drops significantly after 72 hours; educate patients to seek care early if facial weakness develops.

💎 Antivirals are not routinely recommended: Despite theoretical benefit (HSV-1 hypothesis), high-quality trials show no benefit; reserve for severe cases or Ramsay Hunt syndrome.

💎 Eye ointment at night is more important than daytime drops: Corneal exposure is greatest during sleep when eyes remain open for prolonged periods; never miss nighttime lubrication.

💎 Taping the eye is superior to patching: Gentle taping in a downward direction closes the eyelid more physiologically than a patch.

💎 "Crocodile tears" (gustatory lacrimation) is a late sign of aberrant regeneration: Eating triggers tearing due to misdirected parasympathetic fibers regenerating to lacrimal gland instead of salivary gland; indicates synkinesis.

💎 Steroids in pregnancy are safe and necessary: Prednisolone is minimally transferred across the placenta; benefits far outweigh minimal fetal risk; withholding treatment risks permanent maternal facial weakness.

Disposition Pearls

💎 Most Bell's palsy patients can be discharged: With prescriptions for prednisolone, eye care supplies, and follow-up arranged.

💎 Red flags requiring admission or urgent imaging:

• Bilateral facial weakness (GBS risk → ICU for respiratory monitoring)
• Forehead sparing (stroke → hyperacute stroke unit)
• Multiple cranial nerve palsies (brainstem or meningeal process)
• Severe otalgia with mastoid tenderness (mastoiditis → ENT, IV antibiotics)

💎 Follow-up timeline:

• 2-4 weeks: Primary care or neurology review to assess early recovery
• 3-4 months: If no improvement, order MRI and refer to neurology/ENT to exclude tumor
• Immediate ophthalmology: If incomplete eye closure despite maximal effort, eye pain/redness, or vision changes

---

Summary: Bell's Palsy at a Glance

---

Advanced Management Considerations

Electrodiagnostic Testing and Prognostication

Electroneurography (ENoG):

• Measures compound muscle action potential (CMAP) amplitude from facial muscles in response to electrical stimulation of facial nerve
• Performed at 10-14 days after onset (before this, Wallerian degeneration is not complete and test unreliable)
• Compares affected side to normal side
• > 90% degeneration indicates severe axonal injury and poor prognosis (likely incomplete recovery)
• May guide surgical decompression decisions in selected cases (controversial)

Electromyography (EMG):

• Assesses voluntary motor unit potentials and spontaneous activity (fibrillation potentials, positive sharp waves)
• Fibrillation potentials at 2-3 weeks confirm axonal degeneration
• Polyphasic potentials during recovery indicate reinnervation
• Useful at 4-6 weeks to predict recovery trajectory

Prognostic Value:

• Patients with > 90% ENoG degeneration and complete denervation on EMG have less than 50% chance of complete recovery
• Used primarily in research settings; not routinely performed in clinical practice
• Limited utility in changing management in most cases (steroids are given empirically to all)

---

Surgical Management Options

Facial Nerve Decompression:

• Controversial: No high-quality RCT evidence supports routine use
• Rationale: Release pressure on facial nerve in the facial canal by removing bone overlying the narrowest segments (labyrinthine, meatal foramen)
• Proposed indications (highly selective):
  • Complete paralysis (House-Brackmann VI) within 2 weeks of onset
  • ENoG showing > 90% degeneration at 10-14 days
  • Failed corticosteroid therapy
  • Rapidly progressive paralysis
• Approach: Transmastoid or middle cranial fossa approach to decompress labyrinthine and geniculate ganglion segments
• Risks: Hearing loss, CSF leak, intracranial complications, facial nerve injury
• Evidence: Insufficient data to recommend routine use; consider only in highly selected cases at specialized centers with experienced surgeons [17]

Surgical Eye Protection:

• Gold weight implant: Small gold weight (0.8-1.6 g) sutured to upper eyelid tarsal plate; gravity closes eyelid during blinking
  • "Indications: Persistent lagophthalmos > 3-6 months, exposure keratopathy despite maximal medical management"
  • Reversible (can be removed if facial function recovers)
  • "Complications: Migration, extrusion, astigmatism, overclosure"
• Platinum chain implant: Alternative to gold (less magnetic artifact on MRI)
• Lateral tarsorrhaphy: Surgical partial closure of lateral eyelid margins
  • "Indications: Severe lagophthalmos, corneal ulceration, failed conservative management"
  • Temporary (can be reversed) or permanent
  • "Complications: Cosmetic, narrowed palpebral fissure, limitation of lateral gaze"
• Botulinum toxin to levator palpebrae superioris: Induces temporary ptosis to reduce lagophthalmos
• Lower eyelid tightening: For ectropion or lower lid laxity contributing to exposure

Surgical Management of Sequelae:

• Selective neurectomy: For severe synkinesis or hemifacial spasm refractory to botulinum toxin
• Facial reanimation procedures (for permanent paralysis):
  • "Cross-facial nerve graft: Harvest sural nerve, connect to contralateral facial nerve branches, reroute to paralyzed side"
  • "Masseteric nerve to facial nerve transfer: Reroute branch of trigeminal nerve (masseter) to facial nerve"
  • "Hypoglossal-facial nerve transfer: Connect CN XII to CN VII (causes tongue weakness)"
  • "Free functional muscle transfer: Gracilis muscle free flap with microvascular anastomosis and nerve coaptation"
  • "Static procedures: Fascia lata slings, temporalis tendon transfer for static support of lower face"

---

Management of Synkinesis

Synkinesis (aberrant regeneration) affects 15-20% of Bell's palsy patients, particularly those with severe initial paralysis. Management is challenging and often requires multimodal approach.

Clinical Features:

• Ocular-oral synkinesis: Eye closure triggers mouth movement or vice versa
• Gustatory lacrimation ("crocodile tears"): Eating triggers tearing
• Platysma-oral synkinesis: Neck muscle contraction with smile

Management Options:

1. Botulinum Toxin Injections (First-Line):

• Mechanism: Chemodenervation of overactive muscles reduces unwanted movement
• Technique: Inject botulinum toxin A (Botox, Dysport) into specific muscle groups causing synkinesis
  • "Example: Periocular injection for eye closure synkinesis"
  • Perioral injection for mouth movement synkinesis
• Dosing: Highly individualized; 2.5-10 units Botox per site
• Frequency: Every 3-6 months
• Evidence: Multiple case series demonstrate significant improvement in synkinesis severity and quality of life
• Complications: Temporary weakness, asymmetry, ptosis, dry eye

2. Facial Neuromuscular Retraining:

• Mime therapy: Structured exercises to retrain facial movements and reduce synkinetic patterns
• Biofeedback: EMG or mirror feedback to improve selective motor control
• Duration: 6-12 months of supervised therapy
• Evidence: Moderate-quality evidence supports benefit [21]

3. Selective Neurectomy (Refractory Cases):

• Surgical division of specific facial nerve branches causing problematic synkinesis
• Reserved for severe, refractory cases unresponsive to botulinum toxin

---

Special Clinical Scenarios and Problem-Solving

Scenario 1: Pregnant Patient with Bell's Palsy

Case: 32-year-old woman, 34 weeks pregnant, presents with 24-hour history of right facial weakness. Cannot close right eye, right-sided mouth droop. No other neurological deficits. Vitals: BP 145/92 mmHg.

Key Considerations:

1. Pre-eclampsia association: BP 145/92 raises suspicion; check urine protein, labs (platelets, liver enzymes, creatinine)
2. Corticosteroids in pregnancy: Prednisolone is safe (FDA category C; minimal placental transfer)
3. Obstetric consultation: Inform obstetric team due to pre-eclampsia association

Management:

• Prednisolone 60 mg daily × 7-10 days: Benefits outweigh minimal fetal risk
• Eye protection: Artificial tears, ointment, nighttime taping—education critical
• Blood pressure monitoring: Rule out/manage pre-eclampsia
• Reassurance: Prognosis similar to non-pregnant patients
• Follow-up: Coordinate with obstetrics and neurology

---

Scenario 2: Recurrent Ipsilateral Bell's Palsy

Case: 45-year-old man with history of Bell's palsy 3 years ago affecting left side (full recovery). Now presents with new left-sided facial weakness over 48 hours.

Key Considerations:

1. Recurrence on same side is atypical (70% of recurrences affect opposite side)
2. High suspicion for structural lesion: Tumor (parotid, CPA, facial nerve schwannoma), cholesteatoma
3. Requires imaging: MRI brain and temporal bones with gadolinium

Management:

• Treat as Bell's palsy initially: Prednisolone, eye protection (within 72 hours)
• Urgent MRI: Order within 1-2 weeks
• ENT referral: For evaluation of parotid/temporal bone pathology
• Comprehensive examination: Assess for parotid mass, hearing loss, other CN deficits

Differential for Recurrent Ipsilateral Facial Palsy:

• Parotid tumor (malignant > benign)
• Facial nerve schwannoma
• Cholesteatoma
• Chronic otitis media with facial canal dehiscence
• Melkersson-Rosenthal syndrome (recurrent facial palsy + fissured tongue + facial edema)

---

Scenario 3: No Improvement at 3 Months

Case: 52-year-old woman with Bell's palsy treated with prednisolone within 48 hours. Now 3 months post-onset with persistent House-Brackmann Grade IV weakness.

Key Considerations:

1. No improvement by 3-4 months is atypical: Rule out misdiagnosis (tumor)
2. Imaging mandatory: MRI brain with gadolinium
3. Specialist referral: Neurology or ENT for further management

Management:

• MRI brain and temporal bones with gadolinium: Exclude CPA tumor, facial nerve schwannoma, parotid mass, cholesteatoma
• Neurology/ENT referral: Consider electrodiagnostic testing (EMG/ENoG) to assess for ongoing denervation
• Eye protection ongoing: Continue meticulous eye care if lagophthalmos persists
• Consider ophthalmology: For gold weight implant or tarsorrhaphy if corneal risk
• Facial physiotherapy: Initiate or continue neuromuscular retraining
• Counselling: Discuss likelihood of incomplete recovery, synkinesis risk, long-term sequelae

Possible Diagnoses if MRI Abnormal:

• Cerebellopontine angle tumor (vestibular schwannoma, meningioma)
• Facial nerve schwannoma
• Parotid tumor
• Perineural spread of malignancy (skin cancer, parotid cancer)
• Cholesteatoma with facial nerve involvement

---

Scenario 4: Bell's Palsy in a Diabetic Patient

Case: 58-year-old man with poorly controlled type 2 diabetes (HbA1c 9.8%) presents with right facial weakness for 36 hours. House-Brackmann Grade IV.

Key Considerations:

1. Diabetes is a risk factor for Bell's palsy and worse prognosis
2. Corticosteroids will worsen glycemic control: Monitor glucose closely, adjust diabetic medications
3. Higher risk of malignant otitis externa: Pseudomonas skull base osteomyelitis in diabetics
4. Consider antiviral therapy: Some evidence suggests benefit in severe cases

Management:

• Prednisolone 60 mg daily × 7-10 days: Benefits outweigh glycemic risks
• Glucose monitoring: Check capillary glucose BID-QID; warn patient about hyperglycemia
• Adjust diabetic medications: May need temporary insulin or increased oral hypoglycemics
• Consider valacyclovir: 1g TID × 7 days given severity (House-Brackmann IV)
• Eye protection: Diabetics may have reduced corneal sensation—meticulous eye care
• Exclude malignant otitis externa: Examine ears carefully; if otalgia, consider CT temporal bones
• Close follow-up: Review at 2 weeks; diabetics may have slower/incomplete recovery

---

Scenario 5: Bilateral Facial Weakness in a Hiker

Case: 28-year-old woman returns from hiking in New England 2 weeks ago. Develops bilateral facial weakness over 3 days. Unable to close either eye, difficulty eating. No limb weakness. Recalls tick bite on leg (removed 10 days ago).

Key Considerations:

1. Bilateral facial palsy is NEVER Bell's palsy
2. Tick bite + endemic area = Lyme disease until proven otherwise
3. Do NOT give corticosteroids for Lyme neuroborreliosis
4. Other differentials: GBS, sarcoidosis, carcinomatous meningitis

Management:

• Lyme serology: ELISA + Western blot (IgM and IgG)
• Lumbar puncture: CSF analysis (cell count, protein, glucose, Lyme PCR/antibodies)
• Clinical diagnosis of Lyme neuroborreliosis: Tick exposure + bilateral facial palsy + endemic area
• Antibiotic therapy:
  • "Oral: Doxycycline 100 mg BD × 14-21 days (if no CNS involvement)"
  • "IV: Ceftriaxone 2g daily × 14-28 days (if CSF pleocytosis or meningeal signs)"
• Do NOT give corticosteroids: May impair immune response to Borrelia
• Eye protection: Critical—bilateral lagophthalmos
• Monitor for GBS: Assess reflexes, limb strength, vital capacity (if concern for respiratory compromise, admit ICU)

Differential for Bilateral Facial Palsy:

1. Lyme disease (most common in endemic areas)
2. Guillain-Barré syndrome (ascending weakness, areflexia, CSF albuminocytologic dissociation)
3. Sarcoidosis (Heerfordt syndrome: uveitis, parotid swelling, facial palsy, fever)
4. Carcinomatous meningitis (malignant cells in CSF; breast, lung, melanoma)
5. HIV seroconversion
6. Tuberculous meningitis

---

Long-Term Follow-Up and Outcomes

Expected Recovery Timeline

Patients Who Achieve Complete Recovery (House-Brackmann Grade I):

• 80-85% with corticosteroid treatment [5,6]
• Typically by 3-6 months
• Low risk of recurrence (7-10% over lifetime)
• Reassure and discharge from neurology follow-up

Patients With Incomplete Recovery (House-Brackmann Grade II-IV at 6-12 months):

• 10-15% of patients
• Management:
  • Facial physiotherapy and neuromuscular retraining
  • Assess for and manage synkinesis (botulinum toxin)
  • Psychological support (facial disfigurement)
  • Ongoing eye care if lagophthalmos persists
  • Consider surgical options (gold weight, facial reanimation) if permanent

Patients With Poor Recovery (House-Brackmann Grade V-VI at 6-12 months):

• 5% of patients
• Indicates severe axonal degeneration
• Management:
  • Surgical eye protection (gold weight, tarsorrhaphy)
  • Facial reanimation procedures (nerve transfers, free muscle transfer)
  • Specialist facial palsy clinic referral
  • Psychological and social support

---

Quality of Life Considerations

Psychosocial Impact:

• Facial asymmetry affects self-esteem, social interactions, professional life
• Higher rates of depression and anxiety in patients with residual weakness
• Impact on communication (speech, facial expressions)
• Eating difficulties (food retention in cheek, drooling)

Support Resources:

• Facial Palsy UK (https://www.facialpalsy.org.uk/)
• Sir Charles Bell Society (US)
• Psychological counselling and support groups
• Occupational therapy for adaptation strategies

---

Documentation Template for Electronic Medical Record

Emergency Department / General Practice Documentation

Chief Complaint: Acute onset right/left facial weakness

History of Presenting Complaint:

• Onset: [Date/time], sudden vs rapid (over hours to days)
• Maximal weakness within: [24/48/72 hours]
• Prodrome: Retroauricular pain, ear discomfort, viral URI symptoms
• Associated symptoms: Hyperacusis, dysgeusia, dry eye/epiphora, difficulty eating/speaking
• No limb weakness, speech difficulties, visual changes, or other neurological symptoms
• Denies ear vesicles, rash, tick bite

Past Medical History: Diabetes, hypertension, pregnancy, previous Bell's palsy

Examination:

• Cranial Nerve VII:
  • "Forehead: Unable to raise eyebrow or wrinkle forehead on [right/left] (confirms LMN lesion)"
  • "Eye closure: Incomplete closure [right/left] with Bell's phenomenon present"
  • "Smile: Asymmetric, flattened nasolabial fold on [right/left]"
  • "Puff cheeks: Air escapes from [right/left] side"
• House-Brackmann Grade: [I/II/III/IV/V/VI]
• Ear examination: No vesicles, tympanic membrane normal
• Other cranial nerves: Normal (CN II-XII intact except VII)
• Limbs: Normal power, sensation, reflexes, coordination
• No evidence of stroke (forehead involved, no limb weakness)

Diagnosis: Bell's palsy (acute idiopathic unilateral LMN facial nerve palsy)

Differentials excluded: Stroke (forehead involved, no other deficits), Ramsay Hunt (no vesicles), Lyme disease (no tick exposure, not endemic area)

Management:

1. Prednisolone 60 mg PO daily × 7 days (started [date/time], within 72 hours of onset)
2. Eye protection: Artificial tears (preservative-free) every 1-2 hours, lubricating ointment (Lacri-Lube) at bedtime, eyelid taping at night—patient educated
3. Reassurance: 80-85% complete recovery expected within 3-6 months with steroid treatment
4. Safety netting: Return immediately if arm/leg weakness, speech difficulty, severe headache, eye pain/redness, vision changes

Disposition: Discharge home with prescriptions and eye care supplies

Follow-Up: Review with GP or Neurology in 2-4 weeks; if no improvement by 3-4 months, MRI and specialist referral required

---

Patient Education Handout (Summary)

What is Bell's Palsy?

Bell's palsy is a sudden weakness of the muscles on one side of your face. It happens when the facial nerve (the nerve that controls facial movement) becomes inflamed and swollen. The exact cause is not fully understood, but it is thought to be related to a viral infection (often herpes simplex virus) that "reactivates" and causes inflammation.

What are the Symptoms?

• Sudden weakness on one side of your face (over hours to 2-3 days)
• Inability to close your eye on the affected side
• Drooping of your mouth on one side
• Difficulty smiling, eating, or speaking clearly
• Ear pain or discomfort behind the ear
• Increased sensitivity to sounds (hyperacusis)
• Altered taste or dry eye

Is it a Stroke?

No. Bell's palsy affects only the facial nerve and does not involve the brain. In a stroke, the forehead muscles are not affected (you can still raise your eyebrow), whereas in Bell's palsy, the entire side of the face is weak, including the forehead. If you have arm or leg weakness, slurred speech, or vision problems, call emergency services immediately as these are signs of a stroke.

What is the Treatment?

1. Steroid medication (Prednisolone): This reduces inflammation and significantly improves your chances of full recovery. It works best when started within 72 hours of symptom onset. You will take 60-80 mg daily for 7-10 days.

2. Eye protection (CRITICAL): Because you cannot close your eye properly, your eye is at risk of drying out and becoming damaged. You must:

   • Use artificial tears (preservative-free eye drops) every 1-2 hours during the day
   • Apply thick lubricating ointment (Lacri-Lube) at bedtime
   • Tape your eyelid closed at night using hypoallergenic tape
   • Wear glasses or sunglasses outdoors to protect your eye

3. Antiviral medication: Sometimes used in severe cases, but evidence for benefit is weak.

What is the Outlook?

• 80-85% of people treated with steroids make a full recovery within 3-6 months
• Most people start to see improvement within 2-3 weeks
• Eye care is essential to prevent permanent eye damage
• A small number of people (10-15%) may have some residual weakness or unwanted facial movements (synkinesis)

When Should I Seek Urgent Medical Attention?

Return to the emergency department immediately if you develop:

• Weakness in your arm or leg
• Difficulty speaking or understanding speech
• Severe headache
• Eye pain, redness, or vision changes
• No improvement in facial weakness by 3-4 months

Follow-Up

You should be reviewed by your GP or a neurologist in 2-4 weeks to assess recovery. If there is no improvement by 3-4 months, imaging (MRI scan) and specialist referral will be arranged.

---

References

1. Peitersen E. Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl. 2002;(549):4-30. PMID: 12482166.

2. Singh PM, Maini N. Bell's Palsy: A Review. Cureus. 2022;14(10):e30186. doi:10.7759/cureus.30186. PMID: 36397921.

3. Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med. 1996;124(1 Pt 1):27-30. doi:10.7326/0003-4819-124-1_part_1-199601010-00005. PMID: 7503474.

4. Spruance SL. Bell palsy and herpes simplex virus. Ann Intern Med. 1994;120(6):529-530. doi:10.7326/0003-4819-120-6-199403150-00014. PMID: 8185137.

5. Sullivan FM, Swan IRC, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med. 2007;357(16):1598-1607. doi:10.1056/NEJMoa072006. PMID: 17942873.

6. Gronseth GS, Paduga R. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;79(22):2209-2213. doi:10.1212/WNL.0b013e318275978c. PMID: 23136264.

7. Peitersen E. Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl. 2002;(549):4-30. PMID: 12482166.

8. Tiemstra JD, Khatkhate N. Bell's palsy: diagnosis and management. Am Fam Physician. 2007;76(7):997-1002. PMID: 17956069.

9. Goswami N, Khanna S, Khurana AS, Dahiya P, Chauhan R, Sharma A. Ramsay Hunt Syndrome: An Introduction, Signs and Symptoms, and Treatment. Cureus. 2023;15(1):e33688. doi:10.7759/cureus.33688. PMID: 36793818.

10. Hildenbrand P, Craven DE, Jones R, Nemeskal P. Lyme neuroborreliosis: manifestations of a rapidly emerging zoonosis. AJNR Am J Neuroradiol. 2009;30(6):1079-1087. doi:10.3174/ajnr.A1579. PMID: 19450338.

11. Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992;326(17):1130-1136. doi:10.1056/NEJM199204233261706. PMID: 1552914.

12. Chung H, Lee JH, Park JS, Shin JE, Seo JH. Neurotological parameters and prognosis of Bell's palsy patients. Audiol Neurootol. 2015;20(3):185-191. doi:10.1159/000369609. PMID: 25765097.

13. Shmorgun D, Chan WS, Ray JG. Association between Bell's palsy in pregnancy and pre-eclampsia. QJM. 2002;95(6):359-362. doi:10.1093/qjmed/95.6.359. PMID: 12037243.

14. Campbell KE, Brundage JF. Effects of climate, latitude, and season on the incidence of Bell's palsy in the US Armed Forces, October 1997 to September 1999. Am J Epidemiol. 2002;156(1):32-39. doi:10.1093/aje/kwf009. PMID: 12076886.

15. House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985;93(2):146-147. doi:10.1177/019459988509300202. PMID: 3921901.

16. Mat Lazim N, Abdullah B, Salim R, Mathew A. Comparison of 3 Grading Systems (House-Brackmann, Sunnybrook, Sydney) for the Assessment of Facial Nerve Function in Bell's Palsy Using Receiver Operating Characteristic Analysis. Med Sci Monit. 2023;29:e939638. doi:10.12659/MSM.939638. PMID: 37338861.

17. Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell's palsy. Otolaryngol Head Neck Surg. 2013;149(3 Suppl):S1-S27. doi:10.1177/0194599813505967. PMID: 24189771.

18. Gagyor I, Madhok VB, Daly F, et al. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2015;2015(11):CD001869. doi:10.1002/14651858.CD001869.pub6. PMID: 26559436.

19. Jalali MM, Soleimani R, Poorolajal J, Chakherlo A, Ghasemi Boroumand P. Pharmacological Treatments of Bell's Palsy in Adults: A Systematic Review and Network Meta-Analysis. Laryngoscope. 2021;131(8):E2652-E2661. doi:10.1002/lary.29368. PMID: 33404068.

20. Gilden DH, Tyler KL. Bell's palsy--is glucocorticoid treatment enough? N Engl J Med. 2007;357(16):1653-1655. doi:10.1056/NEJMe078179. PMID: 17942879.

21. Khan MU, Coniglio JU, Fonder M, et al. Physical therapy for facial nerve paralysis (Bell's palsy): An updated and extended systematic review of the evidence for facial exercise therapy. Clin Rehabil. 2022;36(11):1424-1448. doi:10.1177/02692155221110727. PMID: 35787015.

22. Berg T, Bylund N, Marsk E, Jonsson L, Kanerva M, Hultcrantz M, Engström M. The effect of prednisolone on sequelae in Bell's palsy. Arch Otolaryngol Head Neck Surg. 2012;138(5):445-449. doi:10.1001/archoto.2012.513. PMID: 22652942.

23. Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan F. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2009;(4):CD001869. doi:10.1002/14651858.CD001869.pub4. PMID: 19821283.

24. Luo L, Liu Z, Feng L, Qin L. Predicting Early Treatment Effectiveness in Bell's Palsy Using Machine Learning: A Focus on Corticosteroids and Antivirals. Int J Gen Med. 2024;17:5377-5390. doi:10.2147/IJGM.S488418. PMID: 39539927.